摘要
Src家族激酶(SFKs)是一组非受体酪氨酸激酶,它的活性主要包括细胞形态学、细胞运动、细胞增殖及生存的调节。这些激酶的异常激活与表达导致很广范围的疾病的发生与发展,如:大量的实体瘤、各种各样的恶性血液病及一些神经元病理。因此,寻找SFK抑制剂是药物化学领域有前景的研究课题。计算方法研究,如:基于受体或者配体的虚拟筛选、对接及分子模拟,证明是鉴别新的SFKs抑制剂的强大工具。在该综述中,我们介绍和分析了计算方法的主要实例,可以鉴定新的SFKs配体和优化先导化合物的活性和药代动力学参数。
关键词: Src羧基端激酶(c-Src)
Current Medicinal Chemistry
Title:Computational Approaches for the Identification and Optimization of Src Family Kinases Inhibitors
Volume: 21 Issue: 28
Author(s): G. Poli, A. Martinelli and T. Tuccinardi
Affiliation:
关键词: Src羧基端激酶(c-Src)
摘要: Src family kinases (SFKs) are a group of non-receptor tyrosine kinases whose activity is involved in the regulation of cellular morphology, motility, proliferation and survival. An aberrant activation and expression of these kinases contribute to the pathogenesis and progression of a broad range of diseases, such as a large number of solid tumors, various hematological malignancies and some neuronal pathologies. The search for SFK inhibitors is therefore a promising research topic in medicinal chemistry. Computational studies such as receptor-based and/or ligand-based virtual screening, docking, and molecular modeling proved to be a powerful tool for identifying new SFKs inhibitors. In this review we report and analyze the main examples of computational approaches that allowed the identification of new SFKs ligands and the optimization of either activity and pharmacokinetic profile of lead compounds.
Export Options
About this article
Cite this article as:
Poli G., Martinelli A. and Tuccinardi T., Computational Approaches for the Identification and Optimization of Src Family Kinases Inhibitors, Current Medicinal Chemistry 2014; 21 (28) . https://dx.doi.org/10.2174/0929867321666140706144419
DOI https://dx.doi.org/10.2174/0929867321666140706144419 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PLK1 Inhibition Radiosensitizes Breast Cancer Cells, but Shows Low Efficacy as Monotherapy or in Combination with other Cytotoxic Drugs
Anti-Cancer Agents in Medicinal Chemistry Neuregulin Signaling in Pieces-Evolution of the Gene Family
Current Pharmaceutical Design Metastatic Colorectal Cancer: Prognostic and Predictive Factors
Current Medicinal Chemistry Ethnobotanical Survey of Medicinal Plants used to Treat Cardiovascular Disorders in Ghasemloo Valley of Urmia City
Cardiovascular & Hematological Agents in Medicinal Chemistry Peptide Self-Assemblies for Drug Delivery
Current Topics in Medicinal Chemistry Review of the Biological Activity of Maslinic Acid
Current Drug Targets Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment
Current Topics in Medicinal Chemistry Identification and Characterization of New Proteins in Podocyte Dysfunction of Membranous Nephropathy by Proteomic Analysis of Renal Biopsy
Current Pharmacogenomics and Personalized Medicine Metabolomics as a Functional Tool in Screening Gastro Intestinal Diseases: Where are we in High Throughput Screening?
Combinatorial Chemistry & High Throughput Screening Hypericin - The Facts About a Controversial Agent
Current Pharmaceutical Design Trans-Platinum Complexes as Anticancer Drugs: Recent Developments and Future Prospects
Current Medicinal Chemistry The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers
Current Cancer Drug Targets Interstitial Lung Disease in Systemic Sclerosis: Pathophysiology, Current and New Advances in Therapy
Inflammation & Allergy - Drug Targets (Discontinued) MicroRNAs: Potential Diagnostic and Therapeutic Targets for Breast Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism
Current Pharmaceutical Biotechnology Gap Junctions as Therapeutic Targets in Brain Injury Following Hypoxia- Ischemia
Recent Patents on CNS Drug Discovery (Discontinued) Porphyrins in Photodynamic Therapy - A Search for Ideal Photosensitizers
Current Medicinal Chemistry - Anti-Cancer Agents HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Peptides Targeting Gap Junctional Structures
Current Pharmaceutical Design Molecular Aspects of FKBP51 that Enable Melanoma Dissemination
Current Molecular Pharmacology